ENVALITH

WIN-Partners Co., Ltd. 2Q Earnings Flash

Medical Equipment sales (+91.1%) and volume growth in core cardiovascular lines lifted 1H operating income 40.9%. With 61.6% progress toward the full-year plan, the focus now shifts to potential 2H upside.

PublishedNovember 4, 2026 at 18:13 GMT+9

Key Positives From The 2Q Results

Revenue rose to JPY 51,600M (+18.0% YoY) and operating income to JPY 2,065M (+40.9% YoY). All six product categories grew YoY. SG&A growth was held below revenue growth, lifting OPM from 3.4% to 4.0%. Earnings had two growth drivers: higher sales volumes in the core cardiovascular area and large Medical Equipment sales.

  • Broad-Based Growth
    : Revenue rose YoY in all six categories. Excluding Medical Equipment, revenue still grew +11.0% (our estimate), so the core consumables franchise delivered double-digit growth.
  • Operating Leverage
    : SG&A rose +10.3% against gross profit growth of +19.0%, so revenue growth flowed through to profit. The SG&A ratio fell from 8.4% to 7.9% (our estimate).
  • Strong 2Q Standalone
    : 2Q standalone (Jul–Sep) revenue was JPY 27,630M (+27.6%) and operating income JPY 1,469M (+92.0%), both our estimates. This more than offset the 1Q profit decline (-15.0%).
  • Stable Gross Margin
    : GPM was 11.9%, flat versus 11.8% a year earlier. Gross margin held even as the equipment sales mix rose.
  • Cardiac Rhythm Management
    : The category grew +11.7% on higher volumes of EP ablation products and pacemakers. As the largest category (26.9% of sales), it underpinned overall growth.

Key Concerns From The 2Q Results

Operating CF plunged to JPY 22M from JPY 1,702M a year earlier. The main drivers were a JPY 2,588M increase in receivables tied to Medical Equipment revenue growth and a JPY 706M inventory build. As a result, profit growth is converting to cash with a lag. Roughly 40% of the revenue increase came from large Medical Equipment sales. These depend on hospital capex projects, so the sustainability of this growth needs ongoing monitoring.

  • Concentrated Growth Driver
    : Medical Equipment accounted for JPY 3,448M of the JPY 7,861M revenue increase (43.9%, our estimate). These sales depend on new construction, expansion/renovation and equipment replacement projects, making them prone to period-to-period volatility.
  • Negative FCF
    : FCF was -JPY 175M (operating CF + investing CF, our estimate). Dividend payments of JPY 1,484M were funded from cash on hand, and cash and cash equivalents fell JPY 1,664M versus the prior fiscal year-end.
  • Quarterly Volatility
    : Quarterly operating income swung sharply, from JPY 596M in 1Q to JPY 1,469M in 2Q (our estimate). Results hinge on the timing of project bookings.
  • Hospital Operating Environment
    : Management noted that hospitals' operating environment remains difficult due to rising materials and energy costs. This raises the risk of weaker hospital capex appetite.
  • Lower Equity Ratio
    : The equity ratio declined from 46.0% to 44.7%. Dividend payments of JPY 1,484M exceeded 1H net income of JPY 1,398M.

Focus Areas / Items To Monitor Going Forward

  • Full-Year Plan Assumptions
    : The full-year operating income plan of JPY 3,350M was maintained. The implied 2H figure of JPY 1,285M is -17.3% versus 2H of the prior year (JPY 1,554M, our estimate). Key questions are the plan's underlying assumptions and the scope for upside.
  • Medical Equipment Pipeline
    : We want to confirm whether large Medical Equipment projects (+91.1%) continue into 2H and next fiscal year. The pipeline of hospital new-build, expansion/renovation and equipment replacement projects will determine revenue scale.
  • Operating CF Recovery
    : Operating CF was compressed by higher receivables. How much it recovers through 2H collections needs to be confirmed, as it underpins dividend funding.
Discussion Points For Management
  • Project pipeline and order backlog for Medical Equipment from 2H onward
  • Assumptions behind the unchanged full-year plan, and the cost and gross margin breakdown implying a 2H operating profit decline
  • Gross margin level for Medical Equipment, and the impact of its rising sales mix on company-wide profitability
  • Timing of collection of receivables built up at 1H-end, and the outlook for working capital normalizing
  • Policy this fiscal year on share buybacks (conducted last fiscal year), and capital policy including the payout ratio

Key Financial Highlights

ItemValueYoY
RevenueJPY 51,600M+18.0%
Gross ProfitJPY 6,117M+19.0%
Gross Profit Margin11.9%Prior year: 11.8%
SG&AJPY 4,052M+10.3%
Operating IncomeJPY 2,065M+40.9%
Operating Income Margin4.0%Prior year: 3.4%
Recurring ProfitJPY 2,104M+41.7%
Interim Net Income Attributable to Owners of Parent CompanyJPY 1,398M+38.1%
EPSJPY 50.87+40.9%
2Q Standalone Revenue (Our Estimate)JPY 27,630M+27.6%
2Q Standalone Operating Income (Our Estimate)JPY 1,469M+92.0%
Cash Flow from Operating ActivitiesJPY 22M-98.7%
└ Change in Trade Receivables-JPY 2,588MPrior year: +JPY 67M
└ Change in Inventories-JPY 706MPrior year: -JPY 253M
└ Change in Trade Payables+JPY 2,211MPrior year: +JPY 533M
  • Recurring Profit Outpaced Operating Income
    : Recurring profit growth (+41.7%) exceeded operating income growth for two reasons. Interest income rose to JPY 38M (prior year: JPY 26M), and restricted stock-related expenses fell from JPY 10M to JPY 0M.
  • Net Income Lagged Recurring Profit
    : Net income growth (+38.1%) trailed recurring profit growth. Gains on sale of fixed assets fell from JPY 9M to JPY 2M, and income taxes rose to JPY 708M (+47.0%).
  • One-Off Base Effect in CF
    : In the prior-year period, proceeds of JPY 671M from the sale of investment securities turned investing CF positive. This one-off item is absent this period, which should be considered in YoY CF comparisons.

Performance By Business Segment

The company operates a single medical device sales segment. By category, all three core cardiovascular categories (ischemic heart disease, cardiac rhythm management and cardiovascular surgery) grew on higher sales volumes. Medical Equipment nearly doubled YoY on the back of successful capex proposals, boosting company-wide growth. Medical Equipment's sales mix rose from 8.7% to 14.0%, while the combined share of the three cardiovascular categories fell from 67.8% to 63.1% (our estimate).

  • Segment Performance Table
  • Revenue By Category
SegmentRevenueYoYOperating IncomeYoYMargin
Medical Device Sales Business (Company-Wide)JPY 51,600M+18.0%JPY 2,065M+40.9%4.0%
Strong Performers
  • Medical Equipment: +91.1% (+JPY 3,448M). The company gathered early intelligence on hospital new builds, expansions/renovations and equipment replacements. It then won orders with capex proposals tailored to local market trends. Products included angiography systems, CT and MRI.
  • Peripheral Vascular Disease and Neurosurgery: +18.4%. Volumes grew for PTA balloon catheters used in percutaneous shunt dilation and for neurosurgery products. Expansion into areas adjacent to cardiovascular is progressing.
  • Cardiac Rhythm Management: +11.7%. Volumes grew for EP ablation products for arrhythmia treatment and for pacemakers. As the largest category, it added JPY 1,448M in revenue.
  • Other: +12.8%. The company strengthened sales efforts toward non-cardiovascular specialties. Handling of gastroenterology and diabetes products (insulin pumps, continuous glucose monitors, etc.) expanded.
Underperformers
  • Ischemic Heart Disease: Revenue grew +7.5%, but this was the slowest growth among the six categories, and its sales mix fell from 22.2% to 20.3%. Patient acquisition support proposals drove volume growth in PTCA balloons and IVUS. As a core product group, its growth trajectory warrants monitoring.
  • Cardiovascular Surgery: +8.8%. Higher TAVI and stent graft volumes delivered revenue growth, but the category trailed the company-wide average (+18.0%).

Progress Rate Versus Full-Year Guidance

At 1H, progress against the full-year plan was 61.6% for operating income and 63.3% for net income. This is well ahead of the prior-year period (operating income 48.5%, net income 47.8%, our estimate). Historically, profits have been weighted toward 2H. The unchanged full-year plan already assumes a 2H operating profit decline, so the likelihood of meeting the plan is high.

ItemValue (2Q Cumulative)Full-Year PlanProgress
RevenueJPY 51,600MJPY 100,000M51.6%
Operating IncomeJPY 2,065MJPY 3,350M61.6%
Recurring ProfitJPY 2,104MJPY 3,380M62.2%
Net IncomeJPY 1,398MJPY 2,210M63.3%
EPSJPY 50.87JPY 80.3763.3%

Changes To Guidance

Full-year guidance is unchanged from the figures announced on May 15, 2026. The implied 2H is revenue of JPY 48,400M (+3.7% versus 2H of the prior year) and operating income of JPY 1,285M (-17.3%), both our estimates. Given 1H progress, these assumptions look conservative. There is upside potential depending on 2H Medical Equipment project bookings.

Commentary On Shareholder Returns

The FY3/27 annual dividend forecast is unchanged at a year-end dividend of JPY 55 (prior year: JPY 54). This implies a payout ratio of 68.4% on forecast EPS of JPY 80.37 (our estimate). There were no share buybacks in 1H, versus JPY 1,037M in the prior-year period. Cash outflows for shareholder returns therefore declined.

Financial Position

The balance sheet carries no borrowings, and cash and deposits stand at JPY 14,267M, keeping the financial position sound. However, dividend payments and higher working capital reduced cash on hand, and the equity ratio fell to 44.7%.

  • Key Figures
  • Leverage Metrics
ItemValueAdditional Information
Cash and Cash EquivalentsJPY 9,267M-15.2% vs. prior fiscal year-end
Cash and DepositsJPY 14,267M-10.4% vs. prior fiscal year-end; includes JPY 5,000M in time deposits with maturities over three months
Notes and Accounts ReceivableJPY 21,092M+13.9% vs. prior fiscal year-end
MerchandiseJPY 4,631M+18.1% vs. prior fiscal year-end
Notes and Accounts PayableJPY 21,638M+10.2% vs. prior fiscal year-end
Total AssetsJPY 51,902M+2.5% vs. prior fiscal year-end
Shareholders' EquityJPY 23,195M-0.4% vs. prior fiscal year-end
Interest-Bearing Debt-No borrowings on the balance sheet
EBITDAJPY 2,243MOperating income + depreciation of JPY 177M (our estimate); prior-year period: JPY 1,595M

Disclosures Released Alongside The Earnings Announcement

None

Major Announcements During The Quarter

None

Large-Shareholding Filings / Material Proposals Over The Past Year

None

Disclaimer

ENVALITH, INC. ("ENVALITH") provides exclusive research coverage services to domestic and international institutional investors, as well as domestic individual investors, with the objective of contributing to the development of global and Japanese capital markets by providing information necessary for considering investments in Japanese listed companies.

  • Purpose and Disclaimer Regarding Investment Decisions

    This report has been prepared solely for informational purposes and does not constitute a solicitation to acquire, sell, or hold securities or any other financial products. Furthermore, this report does not constitute specific investment, financial, or tax advice. Any opinions, judgments, or recommendations contained herein are not intended to induce investment activities. Please be advised that all investment decisions must be made based on the investor's own responsibility and judgment, and ENVALITH and subject company shall not be involved in any such investment decisions.

  • Information Sources, Accuracy, and Disclaimer of Warranty

    This report has been prepared based on a formal request from the subject company, utilizing information provided by and interviews conducted with said company. By using this report, you are deemed to have agreed to the following: 1. Information Sources: This report is prepared on the assumption that the publicly available information and information disclosed by the subject company and provided during interviews is true and reliable. ENVALITH has not independently verified or validated the veracity of such information. 2. Accuracy: The interpretations, analyses, and hypotheses or conclusions based thereon contained in this report are independently derived by ENVALITH using its own perspectives and analytical methods based on the information mentioned in the preceding paragraph. 3. Disclaimer of Warranty: In the event that there are errors or omissions in the information disclosed by the subject company, ENVALITH and subject company shall not be held liable for any inaccuracies in this report resulting therefrom. ENVALITH and subject company make no warranties, whether express or implied, regarding the accuracy, safety, validity, completeness, or any other aspect of this report, nor regarding the past or future performance of the subject company.

  • Limitation of Liability

    ENVALITH and subject company shall not be liable for any costs, damages, or losses (including direct, indirect, incidental, consequential, or punitive damages) arising from the use of this report or the information obtained therefrom. Users of this report acknowledge and agree that such use is at their own risk.

  • Potential Conflicts of Interest

    ENVALITH may have, or may have in the future, business relationships with the subject company. Accordingly, investors should be aware that conflicts of interest may exist that could affect the objectivity of this report.

  • No Obligation to Change or Update Content

    The contents and opinions in this report, as well as the information upon which it is based, are current as of the date of preparation and are subject to change without notice. Please be advised that ENVALITH is under no obligation to update the contents of this report, and investors must verify the timeliness of the information on their own.

  • Governing Language

    This report is prepared in Japanese, English, and Chinese. In the event of any discrepancy or difference in interpretation between the language versions, the Japanese version shall be treated as the original and shall prevail.

  • Copyright

    All rights (including copyrights) relating to this report belong to ENVALITH. Any reproduction, redistribution, or other use of all or part of this report without the prior written permission of ENVALITH is strictly prohibited.

  • Use for Other Investment Products

    Except where ENVALITH has provided prior written approval, the use of this report and the trademarks or trade names of ENVALITH or the subject company in connection with the information distribution, transaction, sales promotion, or advertising of any investment products (including derivatives, structured products, investment trusts, or investment assets whose price, return, or performance is based on or linked to this report) is strictly prohibited.